Clinical trials: Tamoxifen, open to volunteers
Breast Cancer, Lymphoma
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the…
- Conditions
- Breast Cancer, Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT01788839
- Testing
- surveys, Blood draw, Transvaginal ultrasounds
- Where
- 7 sites in United States
- Volunteers
- 475 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide…
- Trial name
- NCT06055179
- Testing
- Xiao Chai Hu Tang (XCHT), Irinotecan regimen, Raloxifene
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Malignant Neoplasm
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid…
- Trial name
- NCT06979596
- Testing
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate
- Where
- 60 sites in United States, Argentina and 11 more
- Volunteers
- 250 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer, HER2-positive
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu…
- Trial name
- NCT05035836
- Testing
- Zanidatamab, Letrozole, Tamoxifen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
ERα+ Breast Cancer, ESR1 Gene Mutation
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and…
- Trial name
- NCT04174352
- Testing
- Tamoxifen, FES PET/CT
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women
This study evaluates the long-term effects of adding 2 years of ovarian function suppression (OFS) to tamoxifen therapy in young premenopausal women with hormone receptor-positive breast cancer after chemotherapy.
- Trial name
- ASTRRAIV (NCT07735897)
- Where
- South Korea
- Volunteers
- 1,483 people
- Sponsor
- MedicalExcellence
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer.
- Trial name
- preEMBER (NCT07287098)
- Testing
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Where
- 90 sites in United States, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast…
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- ALISCA-Breast1 (NCT06369285)
- Testing
- Alisertib, Endocrine therapy
- Where
- 53 sites in United States, Portugal and 1 more
- Volunteers
- 225 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
- Trial name
- MAPPER (NCT06361940)
- Testing
- Aromatase inhibitors or tamoxifen
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Medical College of Wisconsin
Ductal Carcinoma in Situ
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the…
- Trial name
- NCT06075953
- Testing
- Tamoxifen, Exemestane, Letrozole
- Where
- 30 sites in United States
- Volunteers
- 400 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Diffuse Large B Cell Lymphoma
Maintenance Hormonal Therapy and DLBCL
the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL
- Trial name
- NCT06355401
- Testing
- Tamoxifen 20mg
- Volunteers
- 100 people
- Sponsor
- Sohag University
Hot Flashes, Breast Cancer
Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation…
- Conditions
- Hot Flashes, Breast Cancer, Acupuncture
- Trial name
- NCT05460819
- Testing
- Acupuncture treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
Breast Cancer, Early-Stage Breast Carcinoma
SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers
SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume with a simultaneous integrated boost of 30 Gy to the clinical target…
- Conditions
- Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Trial name
- SOLIS (NCT07844759)
- Testing
- Stereotactic Radiation Therapy, Endocrine Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Renaissance Institute of Precision Oncology and Radiosurgery
Ductal Carcinoma in Situ, Extensive Disease
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most…
- Conditions
- Ductal Carcinoma in Situ, Extensive Disease, Mastectomy
- Trial name
- HORNEO01 (NCT04666961)
- Testing
- Tamoxifen 20 mg, Anastrozole 1Mg Tab
- Where
- 8 sites in France
- Volunteers
- 262 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)
The main goal of the study is to abandon breast surgery in patients with breast cancer with a clinical complete response (cCR) after neoadjuvant systemic therapy and confirmed pCR using Vacuum-assisted biopsy (VAB) and sentinel…
- Trial name
- VAB (NCT04293796)
- Testing
- Vacuum-assisted biopsy
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer.
- Trial name
- NCT05645536
- Testing
- TOL2506, Tamoxifen, Letrozole tablets
- Where
- 46 sites in United States, Argentina and 4 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.